N/A
Completed N=179
Follow-up Study to Evaluate Sustained Clearance Rates of Actinic Keratoses up to One Year
Actinic Keratoses
Source: ClinicalTrials.gov NCT00668733 ↗
Enrolled (actual)
179
Serious AEs
0.0%
Results posted
Jul 2010
Primary outcomePrimary: Number of Participants With Recurrence of AK Lesions — 52; 41 participants
Summary
The objective of this study was to obtain long-term sustained clearance rates for subjects previously treated with imiquimod creams in studies GW01-0702, GW01-0703, GW01-0704 and GW01-0705.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Recurrence of AK Lesions |
52; 41 | — |
Eligibility Criteria
Inclusion Criteria
- Are willing and able to give informed consent;
- Have successfully completed one of the following studies: GW01-0702, GW01- 0703, GW01-0704, or GW01-0705 and have been determined to be completely clear of AK lesions at the EOS visit in the designated treatment area from the previous study
- Are willing to participate in the study as an outpatient, make visits to the study center for follow-up evaluation, and agree to comply with all study requirements.
Exclusion Criteria
- None. All subjects who meet the inclusion criteria above may participate.
Data sourced from ClinicalTrials.gov (NCT00668733). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.